Locations:
SearchCurrent rate of increase isn’t sustainable
Treatment cost is a major determinant of value in a value-based healthcare system. The rapidly escalating costs of new cancer treatments threaten the sustainability of value-based cancer care.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
There’s no easy fix, says Taussig Cancer Institute Chairman Brian J. Bolwell, MD, FACP, of Cleveland Clinic Cancer Center, but a start is greater collaboration among those with most at stake: healthcare providers, payers and the pharmaceutical industry.
Click here to view more cancer related videos.
Photo Credit ©Russell Lee
PLEASE EMBED VIDEO HERE (video 6 in the drop box link)
Advertisement
Advertisement
Timing and type of side effects differ greatly from chemotherapy
Dedicated multidisciplinary teams support 84 ultra-rare cancers
Sessions explore treatment advances and multidisciplinary care
New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues
Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations
Early communication between oncologists and ophthalmologist warranted
Case-based course delves into latest treatment approaches
Long-term relationship building and engagement key to gaining community trust